Understanding and Modeling Aggressive ER+ Luminal Adenocarcinoma: Toward Effective Therapeutics
Technical Report,01 Sep 2013,31 Aug 2018
Lawrence Berkeley National Laboratory Berkeley United States
Pagination or Media Count:
Our research was designed to further the development of breast cancer therapeutics by generating new, clinically-relevant models of luminal breast cancer. Our goal was to determine the characteristics of tumorigenicity among the many cell subpopulation of breast tumors and to determine how the role of a particular mucin MM correlated with aggressive breast cancer cell behavior. In the course of our research, we discovered a novel connection between p53, laminins and nitric oxide, which steered our research in an unexpected and productive course. Progress during this award includes the ability to isolate 10 different highly purified cell subtypes from fresh non-malignant breast tissue. RNA sequencing from these cell types provided a rich data set for us to analyze. We advanced our ability to perform high resolution imaging of primary tumors to develop a FACS strategy to isolate subpopulations from tumor samples. Our unexpected findings of p53, laminins and nitric oxide signaling allowed us better understand signaling mechanisms that drive breast cell behavior in an aggressive manner. The significance of our findings allowed us to contribute strongly to the understanding of breast cancer progression and opened up avenues for new and effective treatments for breast cancer.
- Medicine and Medical Research